JERUSALEM, November 16, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has been invited to hold an official demonstration of its barcoded syringe locking-device at Israel's National Ministry of Health on November 29.
Several government officials will be present for the demonstration, including Deputy Minister Yaakov Litzman. The ministry is officially headed by Prime Minister Benjamin Netanyahu.
The demonstration will show precisely how the Medisafe 1 device prevents the improper administration of a particular medicine or dosage to a patient, if that dosage is not electronically verified.
"Israel's nationalized health care system is one of the finest in the world," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "We are pleased that officials from the Ministry of Health are taking the time to learn about Medisafe 1 Technologies' life-saving device, and we are hopeful that the Ministry will consider the inherent cost-benefits of mandating the use of our technology at hospitals across the country."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Jacob Elhadad CEO +972-524440000 Jacob.email@example.com
|SOURCE Medisafe 1 Technologies Corp.|
Copyright©2010 PR Newswire.
All rights reserved